Sobi Reports Increase in Q3 Adjusted EBITA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 20 2025
0mins
Should l Buy ?
Source: NASDAQ.COM
Financial Performance: Swedish Orphan Biovitrum AB reported a third quarter loss of 2.89 billion kronor, a significant decline from a profit of 1.46 billion kronor in the previous year, with a loss per share of 8.32 kronor.
Revenue Growth and Future Outlook: Total revenue increased by 13% to 7.78 billion kronor, with expectations for 2025 revenue growth revised to low double-digit percentages, and an adjusted EBITA margin projected in the mid-to-high 30s percentage range.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
